The High Price of Hope: Xenon Pharmaceuticals' Cautionary Tale The biotech sector thrives on hype and high hopes, but sometimes those dreams come crashing down with a thud.
Take Xenon Pharmaceuticals, whose stock skyrocketed 50% in March after positive results were announced for its epilepsy treatment candidate, azetukalner.
However, as of writing, the company has halted enrollment in several studies due to unexpected side effects, and the stock is plummeting accordingly.